Estimation of Off-Label Use of XGEVA (Denosumab) Using Population-Based Databases in Denmark

Trial Profile

Estimation of Off-Label Use of XGEVA (Denosumab) Using Population-Based Databases in Denmark

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone cancer; Bone metastases; Malignant hypercalcaemia; Multiple myeloma; Non-small cell lung cancer; Osteoporosis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 28 May 2015 Status changed from recruiting to completed, as reported by ClinicalTrial.gov.
    • 01 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top